Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Fierce Healthcare
Hims & Hers stock drops 30% after Novo Nordisk terminates deal
Hims & Hers stock plunged 30% on Monday after Novo Nordisk abruptly ended a collaboration to offer direct access to its weight loss drug Wegovy.
Heather Landi
Jun 23, 2025 12:00pm
Novo's longtime CEO Lars Fruergaard Jørgensen to step down
May 16, 2025 9:41am
Roche lays plans for $700M next-gen obesity drug plant in NC
May 12, 2025 10:33am
Drug spending surged in 2024, driven by obesity and oncology meds
May 5, 2025 11:27am
Novo Nordisk offers cheaper Wegovy for all cash-paying patients
Mar 24, 2025 10:15am
Viking taps CordenPharma in $150M obesity drug production deal
Mar 11, 2025 10:25am
